Clinical Trial Update: A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response. [Phase 1]

View source ↗

Summary

Phase 1 study in healthy subjects evaluating LY450139 (semagacestat) on amyloid beta production rate and dose response has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• LY450139 (semagacestat)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Alzheimer Disease | Phase 1 | Status: COMPLETED